Certain members of the cucurbitacin and Withanolide family have been identified that can sensitize some tumor cell lines to cell death (apoptosis) on subsequent exposure of the cells to pro-apoptotic receptor agonists (PARAS) of the TRAIL "death receptors". These PARAS include TRAIL itself, and agonist antibodies to two of its receptors death receptor-4 (DR4 or TRAIL-R1) and death receptor 5 (DR5, TRAIL-R2).
The protein TRAIL has a very interesting characteristic that it can preferentially cause death of cancer cells whereas normal non-transformed cells are unaffected. Thus use of TRAIL or agonist antibodies to its so-called "death receptors" has been a current focus in cancer therapy.
- Use of the compounds with known TRAIL or agonist antibodies such as Mapatumumab or in combination with immunotherapeutic approaches for the treatment of cancer.
- Cucurbitacins and withanolides can be successfully developed in combination with known TRAIL agonist have the potential of new cancer combination therapies without major toxicities.
Thomas J Sayers (NCI), Nancy Booth (Leidos Biomedical Research, Inc.), Alan Brooks (Leidos Biomedical Research, Inc.)
Nancy L. Booth et al. A cell-based high-throughput screen to identify synergistic TRAIL sensitizers. [PubMed: 19089423]
- U.S. Provisional: U.S. Provisional Patent Application Number 61/287,139, Filed 16 Dec 2009
- U.S. Patent Issued: U.S. Patent Number 9,238,069, Filed 26 Oct 2012, Issued 19 Jan 2016